Table 3.
Percentage of all patients within each frailty score category, whole cohort and stratified by treatment outcome.
| OTU @ 9 weeks |
Progressed |
Died |
||||||
|---|---|---|---|---|---|---|---|---|
| X. | Total |
Good |
Int. |
Poor |
No |
Yes |
No |
Yes |
| (N = 514) | (N = 196) | (N = 149) | (N = 169) | (N = 76) | (N = 438) | (N = 141) | (N = 373) | |
| ECOG PS | ||||||||
| 0 | 72 (14.0%) |
33 (16.8%) |
21 (14.1%) |
18 (10.7%) |
9 (11.8%) |
63 (14.4%) |
17 (12.1%) |
55 (14.7%) |
| 1 | 279 (54.3%) |
106 (54.1%) |
84 (56.4%) |
89 (52.7%) |
47 (61.8%) |
232 (53.0%) |
88 (62.4%) |
191 (51.2%) |
| 2 | 148 (28.8%) |
54 (27.6%) |
37 (24.8%) |
57 (33.7%) |
19 (25.0%) |
129 (29.5%) |
32 (22.7%) |
116 (31.1%) |
| 3+ | 13 (2.5%) |
3 (1.5%) |
6 (4.0%) |
4 (2.4%) |
1 (1.3%) |
12 (2.7%) |
4 (2.8%) |
9 (2.4%) |
| Missing | 2 (0.4%) |
0 (0%) |
1 (0.7%) |
1 (0.6%) |
0 (0%) |
2 (0.5%) |
0 (0%) |
2 (0.5%) |
| GO2FS | ||||||||
| Not frail (0–1) |
93 (18.1%) |
45 (23.0%) |
25 (16.8%) |
23 (13.6%) |
16 (21.1%) |
77 (17.6%) |
31 (22.0%) |
62 (16.6%) |
| Slightly frail (2) |
121 (23.5%) |
53 (27.0%) |
32 (21.5%) |
36 (21.3%) |
22 (28.9%) |
99 (22.6%) |
41 (29.1%) |
80 (21.4%) |
| Severely frail (3+) |
298 (58.0%) |
98 (50.0%) |
91 (61.1%) |
109 (64.5%) |
38 (50.0%) |
260 (59.4%) |
69 (48.9%) |
229 (61.4%) |
| Missing | 2 (0.4%) |
0 (0%) |
1 (0.7%) |
1 (0.6%) |
0 (0%) |
2 (0.5%) |
0 (0%) |
2 (0.5%) |
| mCFS | ||||||||
| Fit (1–2) |
174 (33.9%) |
80 (40.8%) |
48 (32.2%) |
46 (27.2%) |
35 (46.1%) |
139 (31.7%) |
63 (44.7%) |
111 (29.8%) |
| Pre-Frail (3–4) |
110 (21.4%) |
38 (19.4%) |
38 (25.5%) |
34 (20.1%) |
15 (19.7%) |
95 (21.7%) |
25 (17.7%) |
85 (22.8%) |
| Frail (5+) |
230 (44.7%) |
78 (39.8%) |
63 (42.3%) |
89 (52.7%) |
26 (34.2%) |
204 (46.6%) |
53 (37.6%) |
177 (47.5%) |
| G8 | ||||||||
| >14 (‘normal’) | 42 (8.2%) |
18 (9.2%) |
19 (12.8%) |
5 (3.0%) |
9 (11.8%) |
33 (7.5%) |
18 (12.8%) |
24 (6.4%) |
| ≤14 (‘abnormal’) | 458 (89.1%) |
171 (87.2%) |
127 (85.2%) |
160 (94.7%) |
63 (82.9%) |
395 (90.2%) |
119 84.4%) |
339 (90.9%) |
| Missing | 14 (2.7%) |
7 (3.6%) |
3 (2.0%) |
4 (2.4%) |
4 (5.3%) |
10 (2.3%) |
4 (2.8%) |
10 (2.7%) |
| CARG | ||||||||
| Low risk (0–5) |
41 (8.0%) |
19 (9.7%) |
13 (8.7%) |
9 (5.3%) |
5 (6.6%) |
36 (8.2%) |
9 (6.4%) |
32 (8.6%) |
| Medium risk (6–9) |
222 (43.2%) |
89 (45.4%) |
61 (40.9%) |
72 (42.6%) |
28 (36.8%) |
194 (44.3%) |
57 (40.4%) |
165 (44.2%) |
| High risk (10–19) |
215 (41.8%) |
73 (37.2%) |
66 (44.3%) |
76 (45.0%) |
35 (46.1%) |
180 (41.1%) |
63 (44.7%) |
152 (40.8%) |
| Missing | 36 (7.0%) |
15 (7.7%) |
9 (6.0%) |
12 (7.1%) |
8 (10.5%) |
28 (6.4%) |
12 (8.5%) |
24 (6.4%) |
Abbreviations: OTU = overall treatment utility, ECOG = Eastern Cooperative Oncology Group, PS Performance Status, GO2FS = GO2 Frailty Score, mCFS = ‘modified’ Clinical Frailty Scale, G8 = Geriatric-8, CARG = Cancer and Aging Research Group.